亿帆医药(002019.SZ)：产品纳入国家医保目录

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that certain self-owned or imported products from its wholly-owned or controlled subsidiaries have been included in the "National Medical Insurance Catalog (2025)" published by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025 [1] Group 1 - The innovative drug Aibegesitin α injection (Yilishu®) has been renewed for inclusion in the National Medical Insurance Catalog [1] - The imported general agent product Dihyaluronic Acid Sodium Injection (Yinikon®) has also been renewed for inclusion [1] - The compound Huangdai tablets (Baisuekang®) have been adjusted to the regular National Medical Insurance Catalog [1]